FDA-Inspected Site

Raritan Pharmaceuticals, Inc.

10 FDA inspections are on record for Raritan Pharmaceuticals, Inc. in East Brunswick, United States.

483· Form 483 issued

East Brunswick, United States · Last updated July 9, 2026

Overview

  • 10 FDA inspections are on record.
  • 6 inspections produced a Form 483.
  • The most recent recorded inspection date is 2025-04-02.

At a glance

Inspections

10

Form 483s

6

EIRs

1

Last outcome

Form 483

Inspection history

FDA inspections on record, most recent first.

InspectionCategoryOutcomeForm 483
26 Mar 2025 – 2 Apr 2025Human Drugs483View 483 →
5 Dec 2017 – 8 Jan 2018Human Drugs483View 483 →
29 Sep 2016 – 20 Oct 2016Human DrugsWLView 483 →
7 Apr 2016 – 14 Apr 2016Human Drugs483On file
19 Sep 2012Not recorded483View 483 →
21 Aug 2012Not recorded483View 483 →
18 May 2011Not recordedClean
30 Oct 2009Not recordedClean
22 Jan 2007Not recordedClean
1 May 2005Not recordedClean

Observations on record

Form 483 observations cited at this site, most recent first.

2 Apr 2025
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Janet A Rajan, Alisha B Patel

2 Apr 2025
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Janet A Rajan, Alisha B Patel

2 Apr 2025
21 CFR 211.165(b)

Microbiological testing

Cited by Janet A Rajan, Alisha B Patel

2 Apr 2025
21 CFR 211.25(a)

Training , Education , Experience overall

Cited by Janet A Rajan, Alisha B Patel

2 Apr 2025
21 CFR 211.67(b)

Written procedures not established/followed

Cited by Janet A Rajan, Alisha B Patel

Investigators

FDA investigators tied to this site in the record.

Recurring citations

CFR citation patterns observed across this site's inspections.

CitationWhat it coversCited
21 CFR 211.160(b)Cited across public-safe Form 483 observations4x
21 CFR 211.192Cited across public-safe Form 483 observations2x
21 CFR 211.100(a)Cited across public-safe Form 483 observations1x
21 CFR 211.105(b)Cited across public-safe Form 483 observations1x
21 CFR 211.142Cited across public-safe Form 483 observations1x
21 CFR 211.142(b)Cited across public-safe Form 483 observations1x
21 CFR 211.150Cited across public-safe Form 483 observations1x
21 CFR 211.165(a)Cited across public-safe Form 483 observations1x
21 CFR 211.165(b)Cited across public-safe Form 483 observations1x
21 CFR 211.165(e)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)(3)Cited across public-safe Form 483 observations1x
21 CFR 211.166(c)(1)Cited across public-safe Form 483 observations1x
21 CFR 211.184(c)Cited across public-safe Form 483 observations1x
21 CFR 211.194(a)(2)Cited across public-safe Form 483 observations1x
21 CFR 211.198(b)(2)Cited across public-safe Form 483 observations1x
21 CFR 211.204Cited across public-safe Form 483 observations1x
21 CFR 211.22(a)Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.25(a)Cited across public-safe Form 483 observations1x
21 CFR 211.25(b)Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)Cited across public-safe Form 483 observations1x
21 CFR 211.84(b)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(1)Cited across public-safe Form 483 observations1x

Full site report

Get the verbatim findings behind Raritan Pharmaceuticals, Inc.'s 6 Form 483s

Source PDFs, verbatim observations, and recurring CFR citations, so your team knows what this site gets cited for.

  • The site's full inspection history, with every Form 483 and its outcome
  • Warning letters and recalls tied to the company behind it
  • Whether recurring CFR citations get closed out or repeat